http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-117684-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87729a8c288798b59d4c537ff5edd381 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06 |
| filingDate | 2019-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3203b63e1964192d2170ec2bda38f93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56b5be5ea77bd4e969182e7cda61c71b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d70a5a7c359c5bd014c04143742d20d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48032b0fc222e0bf01d95131921fdcdd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af80597f9888a081ee17d67fb1eb8a25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8347cb5a6be48b371fa9e9227f8a95ea |
| publicationDate | 2021-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-117684-A1 |
| titleOfInvention | INHIBITORS OF FERROPORTIN AND ITS USE FOR THE TREATMENT OF DISEASES RELATED TO THE INCREASE OF THE LEVELS OF IRON IN SERUM AND THE ABSORPTION OF THE SAME |
| abstract | Compounds derived from [1,3] thiazolo [5,4-d] pyrimidin-7-amine and [1,3] oxazolo [4,5-e] pyridin-4-amine as inhibitors of ferroportin-mediated iron transport, pharmaceutical compositions comprising them and the use thereof for the treatment of diseases mediated by reduced levels of hepcidin, elevated levels of iron or the absorption thereof or increased erythropoiesis either due to stress or other causes and ineffective erythropoiesis such as for example, thalassemia. Claim 1: A compound of formula (1), wherein R¹ is phenyl or a 6-membered heteroaryl, wherein the heteroaryl contains up to two ring heteroatoms, wherein the phenyl and heteroaryl are optionally substituted with one, two, three or four substituents, each of which is independently selected from the group consisting of C₁₋₆ alkyl, halogen, -OR¹ᵃ, -NR¹ᵇR¹ᶜ, -N₃, and -CN; wherein R¹ᵃ, R¹ᵇ, and R¹ᶜ are each independently selected from the group consisting of hydrogen and C₁₋₆ alkyl; R² and R³ are each independently hydrogen or C₁₋₆ alkyl; or R² and R³ taken together with the carbon to which they are attached form a C₃₋₆ cycloalkyl; X¹ and X² are each independently N or CR¹⁰; where R¹⁰ is selected from the group consisting of hydrogen, halogen, -CN, C₁₋₃ alkyl, -OR¹⁵, and -NR¹⁶R¹⁷; where R¹⁵, R¹⁶, and R¹⁷ are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, optionally substituted C₃₋₇ cycloalkyl, and -NRᵍ (CO) Rʰ; where Rᵍ and Rʰ are independently selected from the group consisting of hydrogen and C₁₋₃ alkyl; X³ and X⁴ are each independently N or C; Y¹ is N, O, S, CR¹⁸ or NR¹⁸; and Y² and Y³ are each independently N, O, S, CR¹⁸, CJ¹, NR¹⁸ or NJ¹, provided that at least one, preferably only one, of Y² and Y³ is CJ¹ or NJ¹; where R¹⁸ is hydrogen or C₁₋₃ alkyl; and J¹ is a compound of formula (2); where R²⁰ is selected from the group consisting of hydrogen and C₁₋₆ alkyl; m, n, and o are each independently 0 or 1, provided that the sum of m, n, and o is at least 1; p, q, and r are each independently 0 or 1, provided that the sum of p, q, and r is at least 1; Each RJ¹ᵃ, RJ¹ᵇ, RJ²ᵃ, RJ²ᵇ, RJ³ᵃ, RJ³ᵇ, RJ⁴ᵃ, RJ⁴ᵇ, RJ⁵ᵃ, RJ⁵ᵇ, RJ⁶ᵃ, and RJ⁶ᵇ is independently selected from the group consisting of hydrogen, halogen, hydroxy, C₁₋₃ alkyl, C₃₋₆ cycloalkyl, and a 4-6 membered heterocycle; where two of RJ¹ᵃ, RJ²ᵃ, RJ³ᵃ and R²⁰ or two of RJ⁴ᵃ, RJ⁵ᵃ, RJ⁶ᵃ and R²⁰ or one of RJ¹ᵃ, RJ²ᵃ and RJ³ᵃ, and one of RJ⁴ᵃ, RJ⁵ᵃ and RJ⁶ᵃ taken together with the atom in which they are attached form a C₃₋₆ cycloalkyl or a 4- to 6-membered heterocycle; and R⁴ is 5 to 10 membered C₆₋₁₀ aryl or heteroaryl, each of which is optionally substituted; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2018-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.